Dr. Ledeboer’s primary responsibility is for the medical and technical oversight of the Clinical Microbiology and Molecular Diagnostics Laboratories.  In this role he oversees development and implementation of new assays, oversees and sign out all testing performed in these laboratories, and consults with physician colleagues regarding test results and selection.   He also consults with members of the Division of Anatomic Pathology regarding identification of microorganisms on surgical pathology specimens.

Elverman M, Goddard MA, Mack D, Snyder JM, Lawlor MW, Meng H, Beggs AH, Buj-Bello A, Poulard K, Marsh AP, Grange RW, Kelly VE, Childers MK.

Long-term effects of systemic gene therapy in a canine model of myotubular myopathy.

Muscle Nerve 2017 Mar 29;

$row_pub_specialist_names

Mack DL, Poulard K, Goddard MA, Latournerie V, Snyder JM, Grange RW, Elverman MR, Denard J, Veron P, Buscara L, Le Bec C, Hogrel JY, Brezovec AG, Meng H, Yang L, Liu F, O'Callaghan M, Gopal N, Kelly VE, Smith BK, Strande JL, Mavilio F, Beggs AH, Mingozzi

Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs.

Mol Ther 2017 Apr 05;25(4):839-854

$row_pub_specialist_names

Wu W, Chordia MD, Hart BP, Kumarasinghe ES, Ji MK, Bhargava A, Lawlor MW, Shin JY, Sera F, Homma S, Muchir A, Khire UR, Worman HJ.

Macrocyclic MEK1/2 inhibitor with efficacy in a mouse model of cardiomyopathy caused by lamin A/C gene mutation.

Bioorg Med Chem 2017 Feb 01;25(3):1004-1013

$row_pub_specialist_names

Kutchukian C, Lo Scrudato M, Tourneur Y, Poulard K, Vignaud A, Berthier C, Allard B, Lawlor MW, Buj-Bello A, Jacquemond V.

Phosphatidylinositol 3-kinase inhibition restores Ca2+ release defects and prolongs survival in myotubularin-deficient mice.

Proc Natl Acad Sci U S A 2016 Dec 13;113(50):14432-14437

$row_pub_specialist_names

Dimmock DP, Lawlor MW.

Presentation and Diagnostic Evaluation of Mitochondrial Disease.

Pediatr Clin North Am 2017 Feb;64(1):161-171

$row_pub_specialist_names